Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging technique could help doctors predict cancer treatment response

NCT ID NCT01235052

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a PET scan using a tracer called FMISO can measure oxygen levels (hypoxia) in head and neck cancers. Sixteen patients received the scan before starting radiotherapy. The goal was to see if the amount of hypoxia seen on the scan could predict how well the cancer responded two years later. The results were not used to change treatment, but to see if this imaging method could be useful in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-FMISO (a radioactive tracer used in PET scans)
What this could lead to
If successful, this could help doctors better predict how head and neck cancers will respond to radiotherapy, potentially guiding more personalized treatment plans.
What could go wrong
This was a very small study (16 people) and only looked at whether the scan could predict outcomes—it did not test a new treatment. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

16 people

The number who actually took part.

Start date

Jun 2009

Finished

Jul 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients over 18 * Patients presenting a squamous cell head and neck carcinoma proposed for a radical treatment consisting in conformational radiotherapy with or without chemotherapy or associated targeted therapy * Signed informed consent Exclusion Criteria: * Patients with distant metastases known before inclusion * Patients suffering of a second cancer or treated before by radiotherapy in the tumour site. * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer of head and neck are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck cancer head and neck neoplasm Head and Neck Neoplasms head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer of head and neck Head and neck neoplasms

Contacts and locations

Locations

  • CHU de Bordeaux - Hôpital Pellegrin

    Bordeaux, 33 076, France

  • Hôpital Robert Picqué

    Villenave-d'Ornon, 33882, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.